  Due to the declining instances of organ donation , total artificial heart ( TAH) therapy is of increasing importance for the management of end-stage biventricular heart<symptom> failure<symptom>. We introduce the currently most important established and novel TAH systems ( SynCardia , CARMAT , ReinHeart , BiVACOR) , report clinical outcomes and discuss technical requirements for the successful implementation of TAH therapy as an alternative to cardiac transplantation.